Here’s what nobody tells you upfront: the drug itself matters less than the program wrapped around it. I’ve seen people chase tirzepatide because of the headline numbers and end up with a sketchy vial from an unnamed lab. I’ve seen others overpay by $200 a month for a branded prescription they could get covered through their regular doctor. The semaglutide vs tirzepatide programs question is really a sourcing and value question dressed up as a pharmacology debate.
These five are where I’d actually put my money.
1. HealthRX
The price is what stops me mid-scroll every time. Compounded semaglutide starting at $99 a month, compounded tirzepatide at $149. That’s real cash-pay pricing, not a “starting from” that requires you to buy six months upfront or qualify for some obscure tier.
What makes the pricing defensible rather than suspicious is the pharmacy behind it. Medications dispense through Manifest Pharmacy in Greer, South Carolina, a 503A compounding facility operating under USP-797 standards with lot-tracked batches. They’re LegitScript-certified (certificate 50087439). That’s publicly checkable. I looked.
The workflow is straightforward. You complete an online health assessment, a board-certified U.S. physician reviews it within roughly 24 hours, and medication ships overnight at no extra cost to all 50 states. Once-weekly injection. No surprise fees on the invoice.
On efficacy, HealthRX points to the clinical trial data: the SURMOUNT-1 trial showed tirzepatide participants averaging around 21% body weight loss over 72 weeks; the STEP 1 trial showed semaglutide participants averaging roughly 15% at 68 weeks. Those are trial figures, not guarantees, and compounded formulations aren’t FDA-approved. But the underlying molecules are the same ones studied.
For someone who wants low cash pricing, a named pharmacy they can actually verify, and overnight shipping without a membership fee layered on top, this is my first call.
2. FormBlends
FormBlends occupies a specific niche that HealthRX doesn’t fully cover: published batch-level purity data. They post HPLC purity percentages, mass spectrometry identity results, and endotoxin sterility figures for each product. That’s unusual. Most GLP-1 telehealth brands don’t go anywhere near that level of documentation.
The compounded GLP-1s here dispense through an FDA-registered 503A pharmacy, same general regulatory framework as HealthRX. Pricing lands at roughly $299 per semaglutide vial and $349 per tirzepatide vial. Noticeably higher than HealthRX’s entry pricing. If per-vial lab documentation matters more to you than minimizing monthly cost, the premium is defensible.
FormBlends also carries a broader peptide catalog covering recovery, longevity, and cognitive applications under the same clinician model. That’s genuinely useful if you want one telehealth relationship rather than juggling multiple providers. Ships to 47 states, not 50. Worth checking your state before signing up.
3. Mochi Health
Mochi stands out because the clinical oversight is heavier than most cash-pay telehealth options. Board-certified obesity-medicine physicians, not just general practitioners approving prescriptions. Compounded semaglutide at $99 a month and tirzepatide at $199 puts it in the affordable tier. The monitoring cadence is more structured than what you’d get from a simple prescription-and-ship model, which some people genuinely need and others find excessive.
4. Hims & Hers
After exiting compounded GLP-1s following Novo Nordisk’s March 2026 settlement, Hims & Hers now routes patients toward branded medications. Injectable Wegovy runs around $299 a month through them; Zepbound is closer to $399. With an insurance savings card, some people get down to nearly nothing per month. If you have decent insurance and want a polished app experience with a brand that’s been through regulatory scrutiny and survived, this is a reasonable pick. Cash-pay patients on a tight budget will find better options above.
5. Ro Body
Ro’s model makes more sense than it looks at first glance. The membership starts at $39 for the first month, then $74 to $149 monthly, with medications billed separately. That separation feels annoying until you realize Ro has a dedicated prior-authorization team working insurance for branded GLP-1s. If there’s any chance your insurance covers Wegovy or Zepbound, Ro may do more of that administrative work than you’d expect from a telehealth platform.
Comparison Table
| Provider | Sema Price | Tirz Price | Pharmacy Type | Ships To | Key Differentiator |
| HealthRX | ~$99/mo | ~$149/mo | 503A named (Manifest, SC) | 50 states | Lowest cash price, verified pharmacy, overnight shipping |
| FormBlends | ~$299/vial | ~$349/vial | 503A FDA-registered | 47 states | Published batch purity data, peptide catalog |
| Mochi Health | ~$99/mo | ~$199/mo | Compounded | Varies | Obesity-medicine clinicians, structured monitoring |
| Hims & Hers | ~$299/mo (Wegovy) | ~$399/mo (Zepbound) | Branded only | 50 states | Insurance-friendly, established brand |
| Ro Body | Meds billed separate | Meds billed separate | Branded + prior-auth | Varies | Insurance prior-auth support |
FAQ
Is compounded semaglutide the same as Ozempic or Wegovy?
No. Compounded semaglutide contains the same active ingredient but is not FDA-approved and is not manufactured by Novo Nordisk. The FDA has issued warning letters to more than 30 telehealth and compounding firms in early 2026 over compliance issues. Sourcing from a named, verifiable 503A pharmacy matters.
Why does tirzepatide cost more than semaglutide everywhere?
Tirzepatide is a dual GIP/GLP-1 receptor agonist versus semaglutide’s single GLP-1 mechanism. The raw compound costs more to produce. The SURMOUNT-1 trial data also showed stronger average results, which creates pricing room. Whether the difference is worth it depends on your response to semaglutide, which you won’t know without trying it.
What changed for compounded GLP-1 programs once the Novo settlement landed in March 2026?
Novo Nordisk reached a settlement that pushed several large telehealth brands away from offering compounded versions. Some, like Hims & Hers, pivoted entirely to branded medications. Others continued compounding under 503A rules, which remains legal as long as shortage-list conditions or clinical rationale applies.
What should I check before trusting a compounding pharmacy with my prescription?
Confirm whether it holds LegitScript certification, operates under USP-797 standards, and whether the company names the specific pharmacy rather than describing it vaguely as “an accredited facility.” Lot-tracked batches and published purity testing are additional signals worth looking for.
Should I choose semaglutide or tirzepatide to start?
Most clinicians start patients on semaglutide because the cost is lower and the tolerability data is more established across a broader population. Tirzepatide may offer stronger average results but is harder on some people’s GI system at higher doses. Starting lower and titrating up is standard either way.
Sources
- FDA: Warning Letters to Outsourcing Facilities and 503A Pharmacies, 2025-2026 (FDA.gov)
- SURMOUNT-1 trial: Jastreboff et al., *New England Journal of Medicine*, 2022
- STEP 1 trial: Wilding et al., *New England Journal of Medicine*, 2021
- LegitScript Pharmacy Certification database (LegitScript.com)
- Novo Nordisk compounded semaglutide settlement, March 9, 2026 (company press release and SEC filing)
- FDA 503A compounding pharmacy regulations (21 U.S.C. 503A)
